← Leaderboards
Asha Bhaskaran Pillai
Stanford University
$2,775,962
Attributed
$2,775,962
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $445.6K · FY2008–21$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,775,962 · 3
By mechanism
R01$1,677,342 · 1
K08$652,995 · 1
R56$445,625 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Samuel Strober$36,157,957
- Robert S Negrin$29,816,136
- Judith Anne Shizuru$11,975,284
- Edgar G. Engleman$35,389,843
- Holden T. Maecker$29,621,634
Others in their field
Top investigators on “Non-Malignant”
- Mary M Horowitz · Medical College Of Wisconsin$150,481,524
- Lynn Rosenberg · Boston University Medical Campus$31,553,547
- Bronwen Shaw · Medical College Of Wisconsin$19,560,999
- Ignacio I. Wistuba · Ut Southwestern Medical Center$19,102,478
- Stanley R Hamilton · Johns Hopkins University$18,469,894
- Leslie S Kean · Emory University$16,146,693
Research focus
Non-MalignantOryctolagus CuniculusMouse ModelMaintenanceInterleukin-4In VivoGenerationsEngraftmentLaboratoriesHistocompatibilityCytokineInsightAntithymoglobulinIn VitroBeta ThalassemiaAllogeneic Bone Marrow TransplantationAllogenicBone Marrow TransplantationImmuneImmune ResponseHematological DiseaseCellsConditioningPlay
Grant awards (13)
NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES$441,168
R01 · FY2021 · HL · contact PI
NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES$441,168
R01 · FY2020 · HL · contact PI
NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES$383,750
R01 · FY2019 · HL · contact PI
NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES$27,506
R01 · FY2019 · HL · contact PI
NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES$383,750
R01 · FY2018 · HL · contact PI
NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES$359,056
R56 · FY2015 · HL · contact PI
NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES$86,569
R56 · FY2015 · HL · contact PI
REGULATORY T CELLS, MIXED CHIMERISM: A NOVEL TRANSPLANT STRATEGY FOR THALASSEMIAS$130,599
K08 · FY2012 · HL · contact PI
REGULATORY T CELLS, MIXED CHIMERISM: A NOVEL TRANSPLANT STRATEGY FOR THALASSEMIAS$130,599
K08 · FY2011 · HL · contact PI
REGULATORY T CELLS, MIXED CHIMERISM: A NOVEL TRANSPLANT STRATEGY FOR THALASSEMIAS$130,599
K08 · FY2010 · HL · contact PI
REGULATORY T CELLS, MIXED CHIMERISM: A NOVEL TRANSPLANT STRATEGY FOR THALASSEMIAS$88,395
K08 · FY2009 · HL · contact PI
REGULATORY T CELLS, MIXED CHIMERISM: A NOVEL TRANSPLANT STRATEGY FOR THALASSEMIAS$42,204
K08 · FY2009 · HL · contact PI
REGULATORY T CELLS, MIXED CHIMERISM: A NOVEL TRANSPLANT STRATEGY FOR THALASSEMIAS$130,599
K08 · FY2008 · HL · contact PI